Fig. 6

The effect of NE on the degradation of PGRN. A–C pVICs were added with 800 ng/mL human recombinant PGRN protein or dimethyl sulfoxide (DMSO) and were transfected with red fluorescent virus (Ad-RFP) or Ad-45KD GRN virus for 24 h. Western blot analysis of RUNX2 and OPN in each groups. D, E Detection of mRNA and protein expression of PGRN in pVICs treated with NE for 24 h. F Detection of mRNA expression of PGRN in pVICs treated with NE or Alvelestat for 24 h under OM induction. G-H Western blot analysis of 45KD GRN in each groups. I–K Western blot analysis of PGRN and 45KD GRN in HEK293 cell treated with PGRN, NE, Alvelestat or both. *P < 0.05, **P < 0.01 vs corresponding control groups. NS meant no significant difference. The measurement data are expressed as the mean ± SD. All experiments were independently repeated three times